Respironics' I-neb drug delivery tech:
This article was originally published in Clinica
Executive Summary
Respironics has received US FDA 50(k) market clearance to use its third generation adaptive aerosol delivery (AAD) system for the aerosolisation of liquid medication approved for use with the product. The I-neb AAD inhalation technology continually monitors and automatically adapts to an individual patient's breathing pattern to deliver a precise medication dose during the patient's inhalation phase. It is smaller, quieter and more portable than the firm's previous generation products. Murrysville, Pennsylvania-based Respironics said that I-neb's first application in the US will be at the end of 2005, through biopharmaceutical company CoTherix, which earlier this year received FDA go-ahead to use I-neb as a means of delivering its Ventavis (iloprost) inhalation solution for treating pulmonary arterial hypertension.